Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Public ClinicalTrials.gov record NCT05316155. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants With Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) and evaluate preliminary clinical efficacy. Part 3 (dose expansion) will confirm safety and preliminary clinical activity at the RP2D. Part 4 (RP2D expansion; MoonRISe-2) will assess the overall complete response (CR) in participants with intermediate-risk-non-muscle invasive bladder cancer (IR-NMIBC; means the cancer cells are only in the bladder's inner lining).
Study identification
- NCT ID
- NCT05316155
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 235 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 11, 2022 (Actual)
- Primary completion
- Mar 30, 2028 (Estimated)
- Completion
- Jul 24, 2029 (Estimated)
- Last update posted
- Sep 25, 2026
2022 – 2029
United States locations
- U.S. sites
- 25
- U.S. states
- 17
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham - The Kirklin Clinic | Birmingham | Alabama | 35294 | — |
| University of Southern California | Los Angeles | California | 90033 | — |
| Urology Associates of Denver | Lone Tree | Colorado | 80124 | — |
| Urological Research Network | Hialeah | Florida | 33016 | — |
| Advanced Urology Institute | Largo | Florida | 33771 | — |
| Advent Health Orlando | Orlando | Florida | 32804 | — |
| Advanced Urology Institute 1 | Oxford | Florida | 34484 | — |
| H Lee Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Associated Urological Specialists | Chicago Ridge | Illinois | 60415 | — |
| Urology of Indiana | Greenwood | Indiana | 46143 | — |
| Urologic Specialists of Northwest Indiana | Merrillville | Indiana | 46410 | — |
| University of Kentucky | Lexington | Kentucky | 40506 | — |
| Southern Urology LLC | Lafayette | Louisiana | 70508 | — |
| Greater Boston Urology | Plymouth | Massachusetts | 02360 | — |
| Specialty Clinical Research of St Louis | St Louis | Missouri | 63141 | — |
| Hackensack University Medical Center Urology | Hackensack | New Jersey | 07601 | — |
| Associated Medical Professionals | Syracuse | New York | 13210 | — |
| Levine Cancer Institute, Carolinas HealthCare System | Charlotte | North Carolina | 28204 | — |
| Central Ohio Urology Group | Gahanna | Ohio | 43230 | — |
| Carolina Urologic Research Center | Myrtle Beach | South Carolina | 29572 | — |
| Low Country Urology Clinics | North Charleston | South Carolina | 29406 | — |
| Urology Associates | Nashville | Tennessee | 37209 | — |
| Urology Austin | Austin | Texas | 78745 | — |
| Urology San Antonio Research | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05316155, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 25, 2026 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05316155 live on ClinicalTrials.gov.